Weight loss drugs available again, patients worried

The U.S. Food and Drug Administration has announced the end of shortages for popular weight-loss drugs like Zepbound and Wegovy. This change means these branded medications are now fully available, impacting access to compounded alternatives. Patients who relied on compounded versions, like Maria Rising, are concerned about losing affordable options. The FDA plans to enforce stricter regulations on compounded GLP-1 medications starting March 19, which could limit access for many. Pharmaceutical companies Eli Lilly and Novo Nordisk have seen significant stock increases due to the demand for their drugs. However, they argue that compounded versions are unsafe and are pushing for patients to transition to their branded medications.